TACE对肝癌细胞凋亡与NK细胞受体表达的影响  

The Effect of TACE on the Apoptosis and the NK cell receptor in Hepatocellular Carcinoma

作　　者：严汀华[1] 江金华[2] 阙华星[1] 卢穗万[1] 谢旺荣[3] 李鸿汀[3] 

机构地区：[1]龙岩市第二医院内科,福建龙岩364000 [2]解放军第二军医大学东方肝胆外科医院,上海200438 [3]龙岩市第二医院介入科,福建龙岩364000

出　　处：《临床医药文献电子杂志》2015年第2期203-205,共3页Electronic Journal of Clinical Medical Literature

基　　金：龙岩市医疗领域重点攻关项目(NO:2013LY57)

摘　　要：目的通过研究经导管动脉化疗栓塞(TACE)对肝癌细胞凋亡与自然杀伤(NK)细胞受体表达的变化,分析探讨TACE治疗中晚期原发性肝癌的临床价值。方法取经临床病理证实的原发性中晚期肝癌患者102例,运用采用TDT缺口末端标记TUNEL法和免疫组织化学SP法研究TACE治疗前后肝癌组织中肝癌细胞凋亡与NK细胞受体表达水平。结果 1、TACE治疗后凋亡指数(AI)升高,而增殖指数(PCNALI)降低(P<0.05),差异具有统计学意义;2、TACE治疗后NK细胞活化性受体NKG2D、NKp44、NKp30增多,颜色较深(P<0.05),差异具有统计学意义;活化性受体NKp46未见明显变化(P>0.05),差异无统计学意义;NK细胞抑制性受体CD158b、CD159a降低(P<0.05),差异具有统计学意义。结论 TACE治疗效果可能与诱导肝癌细胞凋亡及NK细胞活化性受体及抑制性受体变化相关联。Objective To explore the effect of transcatheter arterial chemoembolization（TACE） on the apotosis index（ AI）, the PCNA- Labeling index（ PCNA- LI） and the NK cell receptor in hepatocellular carcinoma（ HCC）. Methods One hundred and three HCC specimens verified by histopathology were undergoing TACE. Terminal deox ynucleotidyl transferase-mediated d UTP nick end labeling（TUNEL） and immuno- histo chemistry method were used to observ e the apoptosis and PCNA;meantime eprole the by flow cytometry and immunohisto chemistry method. Results 1.HCCs treated with TACE had a signif-icantly higher AI and a low er PCNALI than those treated wit h surg ical resect ion alone（P〈0.05）. AI w as highly inversely related to PCNA- LI（P〈0.05）. 2. The expressions of NK-activating receptors NKG2 D, NKp44 and NKp30 were statistically higher in HCCs whichwere treated with TACE（P〈0.05）, the expression level of NKp46 showed no significant upregulation, while the expression levels of NK inhibitory receptors CD158 b and CD159 a were decreased（P〈0.05）. Conclusion HCCs treated with TACE could incr ease AI, decrease PCNA- LI,up-regulate the expressions of NKactivating receptors, and down-regulate the NK inhibitory receptors in the hepatic carcinoma.

关 键 词：经导管动脉化疗栓塞 原发性肝癌 细胞凋亡 NK细胞受体 

分 类 号：R735.7[医药卫生—肿瘤]